BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · IEX Real-Time Price · USD
2.250
-0.050 (-2.17%)
Jul 22, 2024, 9:30 AM EDT - Market open
BeyondSpring Employees
BeyondSpring had 36 employees as of December 31, 2023. The number of employees decreased by 37 or -50.68% compared to the previous year.
Employees
36
Change (1Y)
-37
Growth (1Y)
-50.68%
Revenue / Employee
$48,639
Profits / Employee
-$584,056
Market Cap
90.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Alpha Teknova | 211 |
| Hyperfine | 131 |
| HilleVax | 90 |
| InflaRx | 62 |
| Eton Pharmaceuticals | 30 |
| Clearside Biomedical | 30 |
| Eupraxia Pharmaceuticals | 29 |
| Cellectar Biosciences | 20 |
BYSI News
- 2 months ago - BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire
- 2 months ago - BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire
- 2 months ago - BeyondSpring Files 2023 Annual Report on Form 20-F - GlobeNewsWire
- 2 months ago - BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results - GlobeNewsWire
- 4 months ago - BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer - GlobeNewsWire
- 6 months ago - BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K - GlobeNewsWire
- 7 months ago - BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements - GlobeNewsWire
- 9 months ago - BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor - GlobeNewsWire